Low-Dose Intralesional Cemiplimab Shows Promising Efficacy in Early-Stage Cutaneous Squamous Cell Carcinoma: Insights from a Phase 1 Dose-Escalation Study

First-in-human phase 1 study evaluating low-dose intralesional cemiplimab for early-stage cutaneous squamous cell carcinoma (CSCC).
Intralesional administration demonstrated acceptable safety with no grade 3 or higher adverse events.
High visual and pathologic complete response rates observed at week 13, especially with weekly 5 mg dosing.
Findings suggest a promising non-surgical therapeutic option warranting further clinical trials.

Specialty calculators

For clinical reference; use professional judgment.